Diabetic Macular Edema (DME) Clinical Trial
Official title:
A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe
Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01702441 -
Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04543331 -
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
|
||
| Completed |
NCT02424019 -
Phase 4 IOP Signals Associated With ILUVIEN®
|
Phase 4 | |
| Completed |
NCT02633852 -
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
|
Phase 4 | |
| Completed |
NCT04857996 -
Safety, Tolerability and Evidence of Activity Study of UBX1325 in Patients With Diabetic Macular Edema (BEHOLD)
|
Phase 2 | |
| Recruiting |
NCT05919693 -
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
|
Phase 1/Phase 2 | |
| Completed |
NCT04739306 -
Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema
|
Phase 3 | |
| Recruiting |
NCT06116916 -
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
|
Phase 2 | |
| Completed |
NCT02050828 -
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
|
Phase 2 | |
| Recruiting |
NCT03859245 -
Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention
|
N/A | |
| Completed |
NCT02585401 -
Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada
|
N/A | |
| Terminated |
NCT02080091 -
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
|
N/A | |
| Terminated |
NCT04697758 -
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
|
Phase 1/Phase 2 | |
| Terminated |
NCT00936520 -
SAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
|
Phase 1 |